Gsk and curevac to restructure collaboration into new licensing agreement

Gsk acquires full rights to develop, manufacture and commercialize globally mrna candidate vaccines for influenza and covid-19, including combinations curevac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced london, uk, tÜbingen, germany and boston, ma / accesswire / july 3, 2024 / gsk plc (lse/nyse: gsk) and curevac n.v. (nasdaq:cvac) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mrna development activities.
CVAC Ratings Summary
CVAC Quant Ranking